Cabozantinib Treatment in a Phase II Study for Patients With Hepatocellular Carcinoma (HCC) Refractory to PD-1 Inhibitors

  • STATUS
    Recruiting
  • End date
    Dec 7, 2023
  • participants needed
    40
  • sponsor
    University of Leipzig
Updated on 18 October 2021
cabozantinib
TACE

Summary

The CaPture trial is a prospective, multi-centre, non-randomized phase II study. Its aim is to assess feasibility, safety and efficacy signals of Cabozantinib treatment in patients with HCC and prior non-response or disease progression during a PD-1 or PD-L1 inhibitor treatment. Since the potential study population is very small, the sample size has been fixed in advance to N = 40. Time on treatment (TT) will be measured as primary endpoint.

Description

Patients will be recruited at the participating trial sites (up to ten trial sites), which are all specialized in treatment of patients with HCC. Once potential patients are identified by trial physicians, they will be asked for trial participation and informed consent by one investigator of the CaPture trial. Patients included within 4 weeks after diagnosis of failure of preceding PD-1/PD-L1 inhibitory treatment.

After baseline, visits are previewed on a 4weekly (28 days) basis during the whole duration of Cabozantinib study treatment, which can be used for a maximum of 12 months (336 days). The treatment with Cabozantinib will be performed in accordance with the valid license and according to the judgement of the treating physician.The tablet is taken once a day, starting normally with the highest dosage (60 mg). The doses 20mg and 40mg are still available and can be used for dose reduction. During the visits, the patient will be questioned for compliance and side effects and examined for clinical and laboratory parameters.

Response to Cabozantinib should be assessed at least every 12 weeks (84 days) by either CT scan or MRI.

After termination of Cabozantinib study treatment the first follow-up visit takes place one month after the end of therapy in person. Further follow-up visits can be done by phone to collect patient's status and further treatment.

In addition to the time on treatment (TT), survival, response, feasibility, biomarkers, health status and safety should also be tested.

Furthermore there is an concomitant scientific project. The aim of this project is to examinate the association of HCC related biomarkers with response to Cabozantinib in patients treated in the CaPture study. For this, we will analyse liver biopsy samples as well as circulating markers in patients who are willing to participate in the project.

Details
Condition liver cell carcinoma, Adenocarcinoma, HEPATIC NEOPLASM, HEPATOCELLULAR CARCINOMA, Malignant Adenoma, Liver Cancer
Treatment Cabozantinib
Clinical Study IdentifierNCT04767906
SponsorUniversity of Leipzig
Last Modified on18 October 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Patients with diagnosis of locally advanced or metastatic and/or unresectable hepatocellular carcinoma (HCC)
Pre-Treatment with a PD-1/PD-L1 inhibitor for at least one administration which was given as first line or as following line systemic treatment alone or in combination with other systemic or local treatments (e.g. TACE)
Disease progression or end of therapy due to toxicity during/after pre-therapy
CTCAE Grade 2 prior to study registration, with the exception of alopecia
ECOG (Eastern Cooperative of Onco-logy Group) Index 0 or 1
Age 18 years
Written informed consent

Exclusion Criteria

Significant portal hypertension (moderate or severe ascites)
No adequate controlled arterial hypertension (RR > 140/80mmHg)
ALAT/ASAT five times higher then upper normal value
Hepatic encephalopathy (every stage)
Liver cirrhosis Child-Pugh B and C
Known fibrolamellar HCC, sarcomatoid HCC, or cholangiocarcinoma mixed with HCC
Major surgical procedure, other than for diagnosis, within eight weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the study
Severe infection with alteration of general condition within four weeks prior to initiation of study treatment
Severely impaired kidney function (CDK: stadium 4: GFR<30)
Myocardial infarction within 12 months prior to initiation of study treatment
Epilepsy
Heart failure, Cardiac arrhythmia, respectively long-QT syndrome
Severe bleeding or high risk for the development of severe bleeding, including esophageal varices > 1 or esophageal varices with red marks as seen on a lighted stomach scope (endoscopy)
Chronic inflammatory bowel disease (e.g. colitis ulcerosa, diverticulitis, Crohn's disease)
Increased risk of thromboembolism due to medical history or disease
Significant alcohol consumption (>1 drink/day; 1 drink=0.25l beer or 0,1l wine or 2cl spirituous beverages)
Known active HIV infection
Known hereditary galactose intolerance, lactase deficiency, glucose-galactose malabsorption
Prior Cabozantinib use
Ongoing therapy with direct oral anticoagulants (DOAK) / platelet aggregation inhibitor or statine (e.g. Ticagrelor, Clopidogrel)
Predicted life expectancy of less than 6 months
Female patients who do not meet at least one of the following criteria
Postmenopausal women (for at least 1 year before the screening visit) OR
Postoperative status (6 weeks after bilateral ovariectomy with or without hysterectomy) OR
If they are of childbearing potential, agree to practice one highly effective method of contraception and one additional effective (barrier) method at the same time, from the time of signing the informed consent through 4 months after the last dose of study drug, OR
Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the patient. (Periodic abstinence [eg, calendar, ovulation, symptothermal, postovulation methods], withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception. Female and male condoms should not be used together.) OR
Abstinence OR
Vasectomy of the partner
Male patients not using one of the following variants for contraception including a period of 4 months after the completion of the therapy
Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [eg, calendar, ovulation, symptothermal, postovulation methods], withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception. OR
Condition after vasectomy OR
Condom
Participation in any other interventional trials within 28 days prior to initiation of study treatment
Suspected lack of compliance to previous treatments; inability to take the medication
Pregnancy or lactation, or intention of becoming pregnant during study treatment
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note